Get more replies from employers
Send a job-specific resume in minutes.
Ginkgo Datapoints in Boston is seeking a Senior Director of Multiomics to own the vision, execution, and commercial success of our Multiomics business. You will lead a multidisciplinary team of scientists, automation engineers, and bioinformaticians, reporting to the GM of Datapoints.
This intrapreneurial role sits at the frontier of biology and AI, driving go‑to‑market strategy, product expansion, and new readouts such as DRUG‑seq, proteomics, and metabolomics to deliver industry-leading
Our mission is to make biology easier to engineer. Ginkgo is constructing, editing, and redesigning the living world in order to answer the globe’s growing challenges in health, energy, food, materials, and more. Our bioengineers make use of an in-house automated foundry for designing and building new organisms.
Level (Sr. Director) will be set to match the successful candidate's experience.
Location: Boston, MA (Seaport / HQ) Reporting to: General Manager, Ginkgo Datapoints Focus: Scientific Excellence, Commercial Strategy (P&L), Functional Genomics, Arrayed Perturbation Response Profiling & Multiomic Platform Expansion
Ginkgo Datapoints defines the category of the Bio × AI data provider. We work with top pharma, biotech, tech, and techbio companies, and we've built our reputation on high-quality, large-scale, reproducible data generated by automation rather than by hand. We're a fee-for-service partner — our customers own their data, and our incentives are aligned with theirs.
As our Senior Director of Multiomics, you will own the vision, execution, and commercial success of our Multiomics business, including the functional genomics engine behind our Perturbation Response Profiling and Specialized HTS offerings. This is a genuinely intrapreneurial role: you operate at the frontier of business and science, report to the GM of Datapoints, and lead a multidisciplinary team of scientists, automation engineers, and bioinformaticians with GS&A support.
Your primary goal is to scale our arrayed multiomic perturbation platform into the best in the industry, and to own the full P&L for the vertical. The near‑term growth thesis is clear:
The role is anchored in discovery-stage functional genomics, with real room to extend our multiomic work into translational and clinical biomarkers — population‑scale and direct‑to‑consumer rather than regulated diagnostics. If that's the work that excites you most, there's a home for it here.